Friday, December 11 the Board of Directors of Pfizer Inc.
announced a
quarterly dividend increase of from $ 0.38 to $ 0.39 per share that’s payable
March 5, 2020 to holders of record January 29, 2020. This represents a 2.63%
increase over last quarterly dividend.
The transaction to combine Upjohn with Mylan to form
Viatris Inc. closed on November 16, 2020. It is expected that Viatris will
begin paying a quarterly dividend in the second quarter of 2021, at which time
Pfizer’s quarterly dividend will be reduced such that the combined dividend
dollar amount received by Pfizer shareholders, based upon the combination of
continued Pfizer ownership and approximately 0.124079 shares of Viatris which
were granted for each Pfizer share in the spin-off, will equate to Pfizer’s
dividend amount in effect immediately prior to the initiation of the Viatris
dividend.
“Our commitment to returning capital to shareholders is
strong and the dividend increase reflects our continued confidence in the
business and in our scientific pipeline,” stated Dr. Albert Bourla, Pfizer
Chairman and CEO. “It also reinforces that our focus on creating meaningful
value for patients benefits all our stakeholders.”